Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
UTAA-17 by PersonGen BioTherapeutics (Suzhou) for Relapsed Multiple Myeloma: Likelihood of Approval
UTAA-17 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase II for Relapsed Multiple Myeloma. According to...
Data Insights
UTAA-17 by PersonGen BioTherapeutics (Suzhou) for Refractory Multiple Myeloma: Likelihood of Approval
UTAA-17 is under clinical development by PersonGen BioTherapeutics (Suzhou) and currently in Phase II for Refractory Multiple Myeloma. According to...